Register Now: Development of an NIA Practice-Based Research Network to Conduct AD/ADRD Clinical Research

The National Institute on Aging will be hosting a virtual meeting to discuss the potential and planning of a practice-based research network (PBRN) to address the disparities gap with the recruitment and retention of diverse and underserved populations to AD/ADRD clinical research studies.

PBRNs are networks of health care clinicians and practices working together to answer community-based health care questions and translate research findings into practice–they have the potential to directly engage diverse and underserved communities in AD/ADRD clinical research.

When: Friday, April 30, 2021; 2:00 – 5:00 p.m. EDT

Keynote Speakers: Lori Minasian, MD, Deputy Director for the National Cancer Institute (NCI) Division of Cancer Prevention and Jonathan N. Tobin, PhD, Cardiovascular Epidemiologist and Professor in the Department of Epidemiology and Population Health at Albert Einstein College of Medicine

Panel Speakers: Jennifer Manly, PhD, Andrea Gilmore-Bykovskyi, PhD, RN, and Jonathan Jackson, PhD

Who Should Attend: Researchers and other stakeholders who are interested in learning about PBRNs to address AD/ADRD research gaps

Click here to register.

NIA-funded Biotech Company May Be One Step Closer to Developing a Blood-Based Diagnostic for Alzheimer’s Disease

An NIA-funded biotech company may be one step closer to developing a blood-based diagnostic for Alzheimer’s disease.  This biotech company, Amprion, recently received a Breakthrough Device Designation by the FDA for a test developed to detect the alpha-synuclein protein in the cerebrospinal fluid and bloodstream, a known biomarker for Parkinson’s disease.  Such designation by the FDA paves the way for faster development, assessment, and review, and potentially FDA approval of the technology.  Small Business grants from the NIA are enabling Amprion to adopt their test to specifically detect traces of two biomarkers for Alzheimer’s disease, amyloid and tau aggregates, in cerebrospinal fluid and the bloodstream.  With this new FDA designation for their technology, this company may be on track to develop a test that could help facilitate early detection and diagnosis of these devasting diseases.

FoNIA’s Message to President Obama: Increased Funding Needed for Aging Research at NIH

Members of the Friends of the National Institute on Aging have sent a letter to President Obama requesting an increase of $500 million to support biomedical, behavioral and social sciences aging research efforts at the National Institutes of Health for fiscal year 2016.

The letter points out that the 65 and older population is expected to double between 2010 and 2050.  This will come with an increase in the prevalence of diseases disproportionately affecting older people, most notably Alzheimer’s disease.

With this added investment, however, the NIH can:

  • Implement new prevention and treatment clinical trials, research training initiatives, care interventions, and genetic research studies developed to meeting the goals of the National Plan to Address Alzheimer’s disease.
  • Bolster trans-NIH initiatives developed by the NIH GeroScience Interest Group to understand basic cellular and molecular underpinnings of aging as a principal risk factor for chronic disease and to explore common mechanisms governing relationships between aging and chronic disease.
  • Understand the impact of economic concerns on older adults by examining work and retirement behavior, health and functional ability, and policies that influence individual well-being.
  • Support family caregivers by enhancing physician-family communication during end-of-life and critical care.

To read the letter, please click on the link below:
FONIA final FY 2016 OMB

Alzheimer’s from the Frontlines: Challenges a National Alzheimer’s Plan Must Address

Time: November 8, 2011 from 10am to 11am
Location: SVC 203-202 (Capitol Visitor’s Center)
Event Type: congressional, briefing
Organized By: Alzheimer’s Association

The Alzheimer’s Association invites you to a briefing on:

 “Alzheimer’s from the Frontlines: Challenges a National Alzheimer’s Plan Must Address”

 Tuesday, November 8, 2011 from 10 A.M. to 11 A.M.

SVC 203-202 (Capitol Visitors Center)

 Please join us for a Congressional Briefing unveiling an important new report, “Alzheimer’s from the Frontlines: Challenges a National Alzheimer’s Plan Must Address.” This report offers insights and perspectives from the Alzheimer’s community on ten critical challenges the first ever National Alzheimer’s Plan must address. The National Alzheimer’s Project Act (P.L. 111-375), unanimously passed by Congress last year, requires the creation of a National Alzheimer’s Plan to address the rapidly mounting Alzheimer’s disease crisis and will coordinate Alzheimer’s disease efforts across the federal government.

Building on the Association’s commitment to provide a platform for those directly affected by Alzheimer’s, the Association and its more than 70 chapters nationwide hosted over 130 input sessions throughout the country, allowing thousands of individuals to speak on behalf of all Americans counting on this effort to change the trajectory of this devastating disease for the millions affected today and the millions more at risk tomorrow. “Alzheimer’s from the Frontlines” provides a rare and unique window into the real, unrelenting challenges the disease forces on families year after year.

Speakers include:  

  • Harry Johns, President and CEO, Alzheimer’s Association
  • Robert Egge, Vice President of Public Policy, Alzheimer’s Association
  • Garrett Davis, Alzheimer’s Association Ambassador
  • Senator Susan Collins (R- ME) (invited)
  • Senator Mark Warner (D-VA) (invited)
  • Senator Richard Burr (R-NC) (invited)
  • Senator Debbie Stabenow (D-MI) (invited)

Please RSVP to Tonya Buford at [email protected]

The Alzheimer’s Association is the world’s leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer’s. For more information, visit